Quest Diagnostics Inc vs Oatly Group AB - ADR — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Oatly Group AB - ADR trades at $12.93 (market cap $415.98M). The key difference: Quest Diagnostics Inc is far larger — about 63× Oatly Group AB - ADR's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals.
| DGX | OTLY | |
|---|---|---|
Market Cap | $26.21B | $415.98M |
Sector | Health | Consumer Staples |
52-Week High | $238.50 | $18.54 |
52-Week Low | $173.49 | $8.03 |
Enterprise Value | $31.97B | $920.39M |
Dividend Yield | 1.45% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Oatly (OTLY) trades at $13.23, up 0.84% today, with a bullish technical signal supported by moving averages and RSI. The company reported Q2 2026 revenue of $240.1 million, beating expectations, and raised its full-year outlook. However, it remains unprofitable with a net income margin of -13.81% and negative cash flow. Analyst sentiment is mixed with 44% buy ratings, 50% hold, and 6% sell.
Outlook hinges on revenue growth and margin improvements, but risks include high debt, persistent cash burn, and delayed profitability. The stock offers speculative upside if operational turnaround accelerates, yet investors face significant financial stability concerns amid competitive pressures.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →